[Report] Cancer Biomarkers: New Tools for Transforming Cancer Management

Abstract

Introduction

Although novel cancer biomarkers are reported on a weekly basis, only a handful are actually translated into fully validated diagnostic tools. To fully understand the process, we explore the current status of the cancer biomarker fi eld, roadblocks that slow the development process, the cancer biomarker pipeline, as well as the outlook for integrating cancer biomarkers into clinical practice. We also profi le select companies that are actively pursuing cancer biomarker discovery and development.

Get the Answers You Need to Shape Your Strategy

Companies are utilizing cutting-edge technologies to develop, validate, and implement cancer biomarkers for clinical use. What impediments still exist to incorporating promising research into clinical practice? Which biomarkers show the most promise for approval?
Integrating cancer biomarkers into clinical practice is the goal for development companies as well as clinicians. What are the economic challenges to approval? How can regulatory oversight drive approval and adoption of new technologies?
No one company or agency has the necessary scope or expertise to drive the discovery, development, and implementation of sensitive and specifi c biomarkers. Which alliances show the greatest synergy in bringing valid biomarkers to market? Which shared technologies are driving the most encouraging development?

Scope

Trends in Cancer Biomarker Development: Biomarker discovery and validation, as well as the role of the diagnostics.
Emerging Biomarkers in Select Cancers: Bladder, breast, colorectal, lung, pancreatic, prostate, and renal cell.
Profi les of Select Cancer Biomarker Companies: Biomarker Technologies, Ciphergen, Claros Diagnostics, Epigenomics, Exagen Diagnostics, Genesis Genomics, Health Discovery Corporation, Ipsogen, Matritech, Miraculins, Orion Genomics, Phenomenone Discoveries, Power3 Medical Products, Upstream Biosciences.
Challenges: How strategic alliances and interdisciplinary involvement will need to drive development and implementation of emerging biomarker technologies.

Mentioned in This Spectrum Report

Access Genetics
Acrongenomics
Advanced Magnetics
Affymetrix
Agendia
Atairgin Technologies
Applied Biosystems
Arcturus Biosciences
AstraZeneca
AviaraDx
Bayer
Bayer HealthCare
Baylor College of Medicine
BioAlliance Pharma
BioGenex Laboratories
Biomarker Technologies
bioMerieux
Biomira Diagnostics
Biosite
Brigham and Women' s
Hospital
The Burnham Institute
Cangen Biotechnologies
Centocor
Centre National de la
Recherche Scientifi que
Children' s Medical Center
Ciphergen Biosystems
Claros Diagnostics
CMX Research
Cornell Research Foundation
Cytoclonal Pharamaceutics
Cytyc Health
Dade-Behring
Dako
DiaDexus
DiagnoCure
EDP Biotech
Elan
Emory University
EntreMed
Epigenomics
Erasmus MC, University
Medical Center Rotterdam
Exagen Diagnostics
Genaissance Pharmaceuticals
Gene Fluidics
GeneNews
Genentech
Genesis Genomics
Genomic Health
Genzyme
Gerald P. Murphy Cancer
Foundation
Glycominds
Health Discovery Corporation
Henry M Jackson Foundation
for the Advancement of
Military Medicine
Hycor Biomedical
Immunicon
InterGenetics
Intracel
Ipsogen
Inverness Medical Innovations
JTAT
Johns Hopkins University
Johnson & Johnson
Loma Linda University
Matritech
Mayo Foundation for Medical
Education and Research
Medical College of Georgia
Research Institute
Millennium Pharmaceuticals
Miraculins
Mount Sinai Hospital
Myriad Genetics
Nanogen
Nanospectra Biosciences
Nanosphere
Orion Genomics
Ortho-Clinical Diagnostics
Oxford Genome Sciences
Panacea Pharmaceuticals
Pfi zer
Phenomenome Discoveries
Polymedco
Power3 Medical Products
PrecisionMed
Proteome Systems
Quantum Dot
Quest Diagnostics
Qiagen
Roche
Shimadzu
Sloan-Kettering Institute for
Cancer Research
Texas A&M University
Thomas Jefferson University
TriPath Imaging
UB Institute for Lasers,
Photonics, and Biophotonics
University of Michigan
University of Mississippi
Medical Center
University of New Mexico' s
Science and Technology
Corporation
University of Pittsburgh
University of Texas Systems
Upstream Biosciences
Urocor
Ventana Medical System
Vysis
Wako Chemicals USA